By Anna Iizuka | Reading time: ~18 minutes
The GLP-1 Revolution Is Creating a New Category of Supplements — and Formulators Who Move Now Will Own It
Here is a number that should reshape your product development roadmap: one in eight US adults now takes a GLP-1 receptor agonist drug. That is up from one in sixteen just eighteen months earlier, according to a November 2025 KFF Health Tracking Poll. Among Americans with weight loss goals, 27% plan to use GLP-1 medication.
The pharmaceutical GLP-1 market is projected to exceed $200 billion by 2033. But the real opportunity for supplement formulators is not in competing with these drugs. It is in the massive, underserved need that these drugs create.
GLP-1 users eat roughly 20% less. They lose weight rapidly — but research suggests that 40–60% of that weight loss may come from lean muscle mass, not just fat. They experience gastrointestinal side effects. They develop nutrient deficiencies. And a growing body of evidence shows that their long-term success depends on nutritional support that most of them are not getting.
The GLP-1 nutritional support market was valued at $4.1 billion in 2025 and is projected to reach $13 billion by 2035, growing at a 12.2% CAGR. Products with GLP-1-related claims have grown at 124% CAGR over the past five years. The prebiotic supplement segment alone saw a 78% increase in "GLP-1-friendly" claims between 2020 and 2024.
This article is a formulator-level guide to the ingredients, categories, and strategies that define this new market — including how Japanese fermented ingredients offer a uniquely compelling value proposition in GLP-1 support.
1. What GLP-1 Drugs Do — and What They Leave Behind
GLP-1 receptor agonists (semaglutide, tirzepatide, and others) mimic the naturally occurring GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and suppresses appetite. They are remarkably effective: clinical trials show average weight loss of 15–20% of body weight over 68 weeks.
But this efficacy creates secondary challenges that define the companion supplement opportunity:
Muscle loss: GLP-1 drugs reduce overall caloric intake, and protein intake often falls short. Research published in Frontiers in Nutrition (2025) found that the balance of nutrients consumed shifts significantly, with protein intake sometimes falling below maintenance levels. Studies have found that 40–60% of total GLP-1-supported weight loss may come from reductions in lean muscle mass.
Gastrointestinal distress: Nausea, constipation, bloating, and altered gut motility are among the most common side effects of GLP-1 therapy. These symptoms can significantly reduce quality of life and contribute to treatment discontinuation.
Nutrient deficiencies: When you eat 20% less, every vitamin, mineral, and macronutrient drops proportionally — unless you supplement. Folate, choline, iron, calcium, vitamin D, and B-complex vitamins are particularly at risk.
Bone density concerns: Rapid weight loss, combined with reduced calcium and vitamin D intake, creates bone health risks that are especially relevant for post-menopausal women — a significant demographic among GLP-1 users.
Post-treatment weight regain: Data shows that weight regain after discontinuing GLP-1 drugs is significant. Former users need satiety support, metabolic maintenance, and habit-forming nutritional products.
2. Six Categories of GLP-1 Companion Ingredients
For formulators, the GLP-1 companion market breaks down into six distinct ingredient categories, each addressing a specific clinical or consumer need.
Category 1: Protein and Muscle Preservation
This is the largest segment, accounting for an estimated 43% of the GLP-1 nutritional support market. GLP-1 users need high-quality, highly bioavailable protein in formats that work with reduced appetite and smaller portions.
Key specifications for GLP-1-optimized protein ingredients include high PDCAAS scores (ideally 1.0), complete amino acid profiles with strong BCAA content, high digestibility (>95%), and neutral organoleptic properties for easy formulation into beverages, sachets, and small-format foods.
Yeast-derived proteins are emerging as a compelling option in this space because they achieve PDCAAS 1.0 (equivalent to whey), offer allergen-free status, and provide higher BCAA content than many traditional protein sources — all without the dairy or soy allergen concerns that limit other options for GLP-1 users with sensitive digestive systems.
Category 2: Digestive Health — Pre-, Pro-, and Postbiotics
GLP-1 drugs alter gut motility and can disrupt the microbiome. Digestive health ingredients are the fastest-growing sub-segment, with digestive-fiber blends recording 31% year-over-year growth from 2025.
Postbiotic ingredients are particularly well-suited for GLP-1 companion products because they offer the gut health benefits of fermentation without the viability challenges of live probiotics. Postbiotics are heat-stable, require no cold chain, and maintain consistent potency — critical advantages when GLP-1 users may already be experiencing nausea and digestive sensitivity.
Fermented ingredients that support gut flora modulation, reduce Bacteroides populations, and increase Lactobacillus counts directly address the dysbiosis that GLP-1 therapy can exacerbate.
Category 3: Micronutrient Gap-Filling
Multivitamin formulations specifically designed for reduced-calorie diets represent a straightforward but essential category. Key nutrients include iron, B-complex vitamins (especially B12 and folate), vitamin D, calcium, magnesium, and zinc. Formulators should consider bioavailability-enhanced forms that maximize absorption from smaller doses.
Category 4: Natural GLP-1 Secretion Support
This is the most scientifically sophisticated category — and the one with the highest differentiation potential. Rather than supplementing alongside GLP-1 drugs, these ingredients support the body's own GLP-1 production through established biological pathways.
The primary mechanism is through short-chain fatty acids (SCFAs). When fermentable fiber reaches the colon, gut bacteria break it down into acetate, propionate, and butyrate. These SCFAs activate FFAR2 and FFAR3 receptors on intestinal L-cells, triggering the secretion of GLP-1 and PYY (peptide YY). This mechanism is well-established in peer-reviewed research, including studies published in Diabetes, Cell, and Frontiers in Endocrinology.
Ingredients that support natural GLP-1 secretion include soluble fermentable fibers (barley beta-glucan, inulin, resistant starch), fermented foods and postbiotic extracts that promote SCFA-producing bacteria, amino acids (arginine, leucine, glutamine) that activate L-cell receptors, and botanical compounds with preliminary evidence for GLP-1 modulation (berberine, curcumin, cinnamon extract, green tea polyphenols).
A 2022 study published in Biochemical and Biophysical Research Communications specifically demonstrated that both arabinoxylan and beta-glucan from barley promote GLP-1 secretion by increasing short-chain fatty acid production — providing a direct scientific link between barley-based fermented ingredients and GLP-1 support.
Important note for formulators: Natural GLP-1 support ingredients should be positioned as complementary to healthy metabolic function — not as alternatives to pharmaceutical GLP-1 drugs. The effects of natural compounds are mild compared to prescription medications, and responsible positioning is essential for regulatory compliance and consumer trust.
Category 5: Bone Health
Rapid weight loss accelerates bone mineral density loss. Plant-based calcium with superior bioavailability, combined with vitamin D and vitamin K2, represents a critical but often overlooked companion category. This is especially relevant for the 35–54 age group, which holds a 30.6% share of the GLP-1 nutritional support market.
Category 6: Metabolic Support
Ingredients that support blood sugar regulation, insulin sensitivity, and metabolic flexibility complement GLP-1 therapy by addressing the underlying metabolic health picture. Alpha-glucosidase inhibitors, AMPK activators, and glucose metabolism modulators all have roles to play in comprehensive GLP-1 companion formulations.
3. Why Japanese Fermented Ingredients Are Uniquely Positioned for GLP-1 Support
Japan's thousand-year fermentation tradition has produced a portfolio of ingredients that align remarkably well with the GLP-1 companion opportunity — not by design, but because the underlying science of fermentation and metabolic health converges naturally.
The SCFA Connection: Fermentation → Short-Chain Fatty Acids → GLP-1
The core scientific mechanism linking fermented ingredients to GLP-1 support is short-chain fatty acid production. Japanese fermented ingredients work through two complementary pathways:
Direct SCFA content: Fermented extracts contain SCFAs and SCFA precursors produced during the fermentation process itself. When consumed, these compounds can contribute to the pool of metabolites that interact with FFAR2/FFAR3 receptors.
Microbiome modulation: Postbiotic ingredients from fermentation promote the growth of SCFA-producing gut bacteria (particularly Lactobacillus and Bifidobacterium species), which in turn produce endogenous SCFAs that stimulate L-cell GLP-1 secretion.
This dual mechanism — direct metabolite delivery plus microbiome support — is difficult to achieve with single-compound ingredients and represents a genuine differentiation opportunity for formulators.
Japanese Fermented Ingredients for GLP-1 Companion Formulations
Several Japanese ingredients map directly to GLP-1 companion categories:
Fermented Barley Extract (Triple Fermentation) — A postbiotic ingredient produced through triple fermentation with lactic acid bacteria, yeast, and koji mold. The fermentation amplifies free amino acid content dramatically (arginine 93x, proline 223x compared to unfermented barley). Clinical data shows gut flora modulation: decreased Bacteroides, increased Lactobacillus. The barley substrate itself is linked to SCFA-mediated GLP-1 secretion through published research. Applications: gut health, sleep support, metabolic wellness. Dosage: 90–330 mg/day.
Fermented Vegetable Extract (6-Month Double Fermentation) — A multi-botanical postbiotic from 40+ fermented vegetables. Clinical data includes approximately 45% reduction in blood acetaldehyde and gut microbiome improvements. Addresses the GLP-1 companion categories of digestive health and liver support. Format: 330 mg/day MC powder, heat-stable, no cold chain.
Yeast Protein 80% — PDCAAS 1.0, 97% digestibility, higher BCAA content than whey, allergen-free. Directly addresses the largest GLP-1 companion category (protein and muscle preservation) without the dairy allergen concerns. Suitable for beverages, sachets, and functional food formats that GLP-1 users prefer.
Postbiotic Immune Support (Heat-Killed Lactobacillus) — A heat-killed preparation with patented immune activation pathways (IFN-alpha, NK cell activation). Addresses immune support needs during weight loss and provides gut-associated immune function support. Plant-origin, heat-stable, no refrigeration required.
Plant-Based Calcium — Addresses the bone health gap for GLP-1 users, particularly in the 35–54 demographic. Offers superior bioavailability compared to calcium carbonate, with a clean-label plant-derived positioning.
Marine Collagen with Chondroitin Sulfate — Low molecular weight (~3,000 Da) collagen peptides that support both skin health and joint integrity during rapid weight loss. The naturally occurring chondroitin sulfate addresses connective tissue support without requiring a separate ingredient.
Formulation Strategy: The GLP-1 Companion Stack
Japanese fermented ingredients enable multi-benefit formulations that address several GLP-1 companion needs simultaneously, reducing capsule count and simplifying product lines:
Gut + Metabolic Support Stack: Fermented barley extract (330 mg) + fermented vegetable extract (330 mg). Total: 660 mg, fits in two capsules. Addresses digestive health, microbiome support, SCFA-mediated metabolic benefits, and liver support.
Complete Companion Stack: Yeast protein (serving-dependent) + fermented barley extract (330 mg) + plant-based calcium (recommended dose). Addresses muscle preservation, gut health, and bone health in a single daily regimen.
The postbiotic nature of these ingredients (heat-stable, no cold chain, consistent potency) makes them particularly practical for the GLP-1 companion market, where consumers are already managing complex medication regimens and prefer simple, reliable supplementation.
4. Market Data and Outlook
The numbers behind the GLP-1 companion opportunity are compelling at every level:
GLP-1 drug market: $62.8 billion (2025) → projected $200+ billion by 2033. As many as one in nine US adults may be using GLP-1 drugs by 2035.
GLP-1 nutritional support market: $4.1 billion (2025) → $13 billion (2035), 12.2% CAGR. Protein and macronutrient blends dominate with 43% share.
Product claim growth: GLP-1-related product claims have grown at 124% CAGR over five years. North America accounts for 83% of this growth.
Consumer behavior shift: GLP-1 users reduce grocery spending by 11% on chips/snacks, 9% on bakery items, 7% on cookies — but increase spending on protein supplements, functional beverages, and targeted nutrition.
Channel expansion: Major retailers including Target are expanding protein and dietary support offerings specifically for GLP-1 consumers. Digital health platforms and telehealth are driving personalized supplementation recommendations.
For ingredient suppliers, the window of opportunity is now. Brands are actively seeking clinically backed, clean-label ingredients that can be formulated into GLP-1 companion products. First movers with differentiated ingredient stories and strong technical documentation are securing long-term supply agreements.
5. What This Means for Your Next Product
The GLP-1 companion market is not a trend — it is a structural shift in how consumers approach weight management and metabolic health. For formulators and brand owners, the strategic implications are clear:
Position as companion, not alternative. Products should support GLP-1 therapy, not compete with it. This is both a regulatory imperative and a market positioning advantage.
Think lifecycle, not single product. GLP-1 users have different needs at different stages: pre-treatment (metabolic preparation), active use (side effect management, nutrient gaps), and post-treatment (weight maintenance, metabolic support). Each stage represents a distinct formulation opportunity.
Prioritize multi-benefit ingredients. GLP-1 users are already taking medication daily. Every additional supplement competes for compliance. Ingredients that address multiple needs (gut health + metabolic support, protein + satiety) reduce capsule burden and improve adherence.
Invest in clinical backing. The GLP-1 consumer is medically engaged and evidence-aware. Clinical data, published research, and transparent sourcing are table stakes in this market.
Consider format innovation. Reduced appetite means smaller portions. Ready-to-drink formats, sachets, functional beverages, and concentrated powders align better with GLP-1 user preferences than traditional large capsules or tablets.
Explore GLP-1 Companion Ingredients from Japan
Iizuka Shoukai supplies clinically backed Japanese fermented ingredients, proteins, and functional raw materials for GLP-1 companion supplement formulations. We provide samples, full technical documentation, formulation guidance, and regulatory support for your target markets.
Contact: iizuka.shoukai@gmail.com | iizukashoukai.com
References
1. KFF Health Tracking Poll, November 2025: GLP-1 usage among US adults.
2. Future Market Insights. GLP-1 Nutritional Support Market Size & Share 2025-2035.
3. Innova Market Insights. GLP-1-related product claim growth data, 2020-2024.
4. Neeland IJ, et al. Changes in lean body mass with GLP-1-based therapies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27.
5. Johnson B, et al. Investigating nutrient intake during use of GLP-1 receptor agonists. Frontiers in Nutrition. 2025;12.
6. Tolhurst G, et al. Short-chain fatty acids stimulate GLP-1 secretion via FFAR2. Diabetes. 2012;61(2):364-71.
7. Shimizu H, et al. Arabinoxylan as well as beta-glucan in barley promotes GLP-1 secretion by increasing SCFA production. Biochem Biophys Res Commun. 2022.
8. Silva YP, et al. The role of SCFAs in gut-brain communication. Frontiers in Endocrinology. 2020;11:25.
9. Canfora EE, et al. SCFAs in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. 2020.
10. Kantar-SC Johnson Study, January 2025: GLP-1 impact on grocery spending.
Disclaimer: This article is intended for B2B audiences (formulators, brand owners, R&D professionals). Natural GLP-1 support ingredients should be positioned as complementary to metabolic health, not as alternatives to prescription GLP-1 medications. Regulatory requirements vary by market. Consult local authorities regarding health claims.